Imidazenil

ID: imidazenil

Aliases: Ro 48-6791

Type: compound

Route/form: oral or route depends on studied product

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic

Source types: preclinical

Linked sources: 2

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• benzodiazepine-site GABA-A partial agonist
• subtype-selective GABA-A PAM

Optimization domains

• anxiety
• seizure
• sedation

Research basis

• Subtype/partial agonist profile is interesting for separating anxiolysis/anticonvulsant effects from sedation.
• Useful in mapping better benzodiazepine-like pharmacology.

Limits, risks, and missing evidence

• Not a validated 'perfect benzo'; human efficacy/safety package is not established for general use.
• Dependence, impairment, and interaction assumptions must be tested, not inferred.

Risk flags

• CNS depressant
• dependence unknown
• research

Linked papers, labels, and reviews

1. Imidazenil: a new partial positive allosteric modulator of GABA action at GABAA receptors
   preclinical / pubmed_imidazenil_gabaa_partial_pam_1993
   Foundational imidazenil GABA-A partial PAM and anticonflict/anticonvulsant pharmacology.
2. Lack of tolerance and dependence to repeated administration of the partial benzodiazepine receptor agonist imidazenil in rats
   preclinical / pubmed_imidazenil_dependence_rat_1994
   Direct imidazenil rat tolerance/dependence source; relevant to liability hypotheses but not proof of human safety.